CELL AND GENE THERAPY
Sysmex Corporation | May 17, 2021
Sysmex Corporation and ThinkCyte, Inc. announced today the signing of joint development and investment agreements for the commercialization of an AI-based cell analysis technology in May 2021.
The development of novel testing and diagnostic technologies of high clinical utility is being pursued to improve the precision of diagnoses and maximize treatment as healthcare becomes more accurate and personalized at an increased pace - in combination with the advancement of technology. Meanwhile, telehealth, AI-powered medical imaging analysis, and automated testing of robots are all gaining traction in the healthcare industry.
Sysmex has been acquiring technologies for studying cells, genes, and proteins with high accuracy and sensitivity on a proactive basis. A cell analysis platform is one of the technologies that has been used in a variety of Sysmex products. In this field, Sysmex's current emphasis is on developing technologies that specifically analyze cells using different types of information such as cell function and responsiveness, as well as seeking faster cell analysis.
ThinkCyte has "Ghost Cytometry technology," which analyses morphological information of cells in a quick and simple process, while the information gathered by this technology is much richer than what can be collected using conventional flow cytometry (FCM) technique. This technology, in addition to counting and analyzing cells based on their basic morphological features, helps users to identify each cell based on its specific morphological details in terms of its characteristics and functions. This high-resolution analysis will allow for highly accurate clinical condition determination using body fluids such as blood, improve precision in a wide variety of cell-based diagnoses, and contribute to more personalized healthcare.
On March 31, 2021, Sysmex and ThinkCyte signed a memorandum of understanding to begin full-fledged joint development of the novel AI-based cell analysis technology as a result of ongoing collaborative research between the two companies to increase the viability of applying Ghost Cytometry technology to diagnostic techniques of high clinical value. In addition, on May 1, 2021, the two companies agreed to collaborate on joint development, with the aim of commercializing cell analyzers and testing techniques based on Ghost Cytometry technology for cell analysis (including research) in the field of in-vitro diagnostics (IVD). Meanwhile, on May 11, 2021, Sysmex agreed to make an equity investment in ThinkCyte, which will enable the two companies to enhance their strong partnership.
Sysmex and ThinkCyte have formed an alliance to develop novel cell analysis technology and research techniques by combining Sysmex's IVD capabilities with ThinkCyte's proprietary Ghost Cytometry technology, thereby contributing to the advancement and evolution of healthcare around the world.
About Sysmex Corporation
Sysmex works to contribute to the development of healthcare and people's healthy lives in accordance with its goal of "shaping the advancement of healthcare," as described in the Sysmex Group's corporate ideology, the "Sysmex Way." Sysmex performs integrated R&D, manufacturing, and sales, as well as providing support services for its in vitro blood, urine, and other bodily fluids testing instruments, reagents, and software. Sysmex's products are sold to medical institutions in over 190 countries and regions around the world.
Sysmex has been expanding its business in the life science domain in recent years, using proprietary technologies to develop new testing and diagnostic value, provide healthcare personalized to individual patients, and help patients minimize burdens and improve quality of life.
Read More
CELL AND GENE THERAPY
BioInvent | December 22, 2020
BioInvent International AB ("BioInvent") (OMXS: BINV), a biotech organization focused in on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, and Transgene (Euronext Paris: TNG), a biotech organization that designs and develops infection based for the therapy of cancer, reported they have received administrative endorsement in Belgium for a clinical trial application (CTA) for a Phase l/lla study of the novel oncolytic vaccinia virus BT-001.
BT-001 is a best-in-class oncolytic Vaccinia virus. It has been produced utilizing Transgene's Invir.IO™ stage and its protected large-capacity VVcopTK-RR-oncolytic virus, which has been designed to encode both a Treg- depleting human recombinant anti-CTLA4 antibody response created by BioInvent's proprietary n-CoDeR®/F.I.R.S.T™ stages, and the human GM-CSF cytokine. By specifically focusing on the tumor microenvironment, BT-001 is relied upon to inspire a lot more grounded and more successful antitumoral reaction. Conveying the anti-CTLA4 antibody response straightforwardly to the tumor microenvironment will permit a neighborhood remedial movement and will in this manner enormously increment the security and tolerability profile of the monoclonal immunizer by antibody foundational introduction. BT-001 is being co-created through a 50/50 collaboration among BioInvent and Transgene.
Read More
Stemcyte | March 23, 2022
On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process.
The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorders an appropriate preparative regimen for hematopoietic and immunologic reconstitution. There have been over 40,000 successful umbilical cord blood transplants globally to treat disorders of the hematological and immunological systems and genetic metabolic diseases since the first successful use of umbilical cord blood to treat Fanconi Anemia patients in 1988.
StemCyte has donated more than 2,200 cord blood units for transplantation to 1 in every 20 patients with umbilical cord blood transplants globally during the last 20 years. In addition, at least 350 transplant centers around the world, including well-known medical centers such as UCLA Medical Center, Duke University Hospital, Taiwan Chang Gung Memorial Hospital, and National Taiwan University Hospital, consistently meet the quality standards of international accrediting bodies and are recognized and trusted as safe and effective by StemCyte's products.
Read More